SCHEMBL3473532

SCHEMBL3473532

CCOC(=O)c1cccc(NC(=O)c2ccc(-c3cc(C(F)(F)F)nn3-c3ccccc3Cl)cc2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.50
SMN1; SMN2 Q16637 5/20 0.50
TP53 P04637 2/20 0.50
RXRA P19793 2/20 0.50
NR1H2 P55055 2/20 0.50
NR1H3 Q13133 2/20 0.50
RAB9A P51151 6/20 0.48
NPC1 O15118 4/20 0.48
ALDH1A1 P00352 2/20 0.48
LMNA P02545 1/20 0.48
MAPK1 P28482 1/20 0.48
POLB P06746 3/20 0.48
KMT2A Q03164 2/20 0.48
CYP1A2 P05177 1/20 0.46
PKM P14618 1/20 0.46
MEN1 O00255 1/20 0.45
ABCB1 P08183 1/20 0.45
HTT P42858 1/20 0.45
ABCG2 Q9UNQ0 1/20 0.45
BRAF P15056 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3472786 0.93 MAPT (0.54) MAPTSMN1; SMN2TP53RXRANR1H2
SCHEMBL3472322 0.92 MAPT (0.55) MAPTSMN1; SMN2TP53RXRANR1H2
SCHEMBL3471973 0.89 RXRA (0.55) MAPTSMN1; SMN2TP53RXRANR1H2
SCHEMBL3472273 0.87 MAPT (0.56) MAPTSMN1; SMN2TP53RXRANR1H2
SCHEMBL3473833 0.86 MAPT (0.53) MAPTSMN1; SMN2TP53RXRANR1H2
SCHEMBL3472421 0.86 MAPT (0.55) MAPTSMN1; SMN2TP53RXRANR1H2
SCHEMBL3472847 0.86 RXRA (0.54) MAPTSMN1; SMN2TP53RXRANR1H2
SCHEMBL3473976 0.86 MAPT (0.53) MAPTSMN1; SMN2TP53RXRANR1H2
SCHEMBL3474844 0.85 RXRA (0.55) MAPTSMN1; SMN2TP53RXRANR1H2
SCHEMBL3474587 0.85 RXRA (0.55) MAPTSMN1; SMN2TP53RXRANR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331295-A1 MODULATORS OF LXR NR1H2, NR1H3, NR1H4 MAPT 4737/4885SMN1; SMN2 4666/4885TP53 4318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.